Oxford University Press

SHERPA: Yellow

People

  1. Hudis
    Hudis
  2. Fornier
    Fornier
  3. Norton
    Norton
  4. Dang
    Dang
  5. Goldfarb
    Goldfarb
  6. Gucalp
    Gucalp
  7. Iyengar
    Iyengar
  8. Jhaveri
    Jhaveri
  9. Lake
    Lake
  10. Modi
    Modi

Groups

  1. Breast Medicine Service (8)
  2. Department of Medicine (8)
  3. Solid Tumor Oncology Division (8)
  4. Survivorship Research (7)
  5. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (3)
  6. Epidemiology and Biostatistics (3)
  7. Gynecologic Medicine Service (3)
  8. GDMT, Medicine (2)
  9. Gynecology Disease Management Team (2)
  10. Health Outcomes Research Group (2)
Search Within
  1. "Breast Medicine Service"
  2. "Jose Baselga"
Formats
  1. Journal Article (4)
  2. Meeting Abstract (4)
Groups
  1. Breast Medicine Service (8)
  2. Department of Medicine (8)
  3. Solid Tumor Oncology Division (8)
  4. Survivorship Research (7)
  5. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (3)
  6. Epidemiology and Biostatistics (3)

More Groups

People
  1. Jose Baselga (8)
  2. Clifford Hudis (5)
  3. Larry Norton (3)
  4. Maura Dickler (3)
  5. Monica Fornier (3)
  6. Ayca Gucalp (2)

More People

Years
  1. 2017 (3)
  2. 2016 (1)
  3. 2015 (1)
  4. 2014 (2)
  5. 1993 (1)
Publications
  1. Annals of Oncology (7)
  2. JNCI: Journal of the National Cancer Institute (1)

Results (8)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Primary results of LORELEI: A phase II randomized, double-blind study of neoadjuvant letrozole (LET) plus taselisib versus LET plus placebo (PLA) in postmenopausal patients (pts) with ER+/HER2-negative early breast cancer (EBC)
    Meeting Abstract

    Saura, C.; de Azambuja, E.; Hlauschek, D.; Oliveira, M.; Zardavas, D.; Jallitsch-Halper, A.; de la Pena, L.; Nuciforo, P.; Ballestrero, A.; Fornier, M. N.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-positive metastatic breast cancer after prior pertuzumab-based therapy
    Meeting Abstract

    Iyengar, N. M.; Smyth, L. M.; Lake, D.; Gucalp, A.; Singh, J. C.; Traina, T. A.; Defusco, P.; Dickler, M. N.; Fornier, M. N.; Goldfarb, S. B.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • Oncologist use and perception of large panel next-generation tumor sequencing
    Journal Article

    Schram, A. M.; Reales, D.; Galle, J.; Cambria, R.; Durany, R.; Feldman, D.; Sherman, E.; Rosenberg, J.; D'Andrea, G.; Baxi, S.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-positive metastatic breast cancer after prior pertuzumab-based therapy
    Meeting Abstract

    Iyengar, N. M.; Smyth, L.; Lake, D.; Gucalp, A.; Singh, J.; Traina, T. A.; Defusco, P.; Dickler, M. N.; Fornier, M.; Goldfarb, S.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • Tailoring therapies - Improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
    Journal Article

    Coates, A. S.; Winer, E. P.; Goldhirsch, A.; Gelber, R. D.; Gnant, M.; Piccart-Gebhart, M.; Thürlimann, B.; Senn, H. J.; & Panel Members
    Annals of Oncology (2015)

    Fulltext@MSK | Save
  • A phase III randomized, double-blind, trial comparing sorafenib plus capecitabine versus placebo plus capecitabine in the treatment of locally advanced or metastatic HER2-negative breast cancer (resilience)
    Meeting Abstract

    Baselga, J.; Zamagni, C.; Gomez, P.; Bermejo, B.; Nagai, S.; Melichar, B.; Chan, A.; Mangel, L.; Bergh, J.; Costa, F. P.; more...
    Annals of Oncology (2014)

    Fulltext@MSK | Save
  • Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer
    Journal Article

    Baselga, J.; Manikhas, A.; Cortés, J.; Llombart, A.; Roman, L.; Semiglazov, V. F.; Byakhov, M.; Lokanatha, D.; Forenza, S.; Goldfarb, R. H.; more...
    Annals of Oncology (2014)

    Fulltext@MSK | Save
  • Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies
    Journal Article

    Baselga, J.; Norton, L.; Masui, H.; Pandiella, A.; Coplan, K.; Miller, W. H. Jr; Mendelsohn, J.
    JNCI: Journal of the National Cancer Institute (1993)

    Fulltext@MSK | Save